Libby S Wolf, NP
Nurse Practitioner · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 12 years
- Graduated 2014
Offices
1 location · Regents of the University of California · 706 clinicians in this group
Looking this up.
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Libby S Wolf’s office at (415) 476-4029 to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$30,169
Medicare paid this office $30,169 for 145 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 90 | $13,259 | $105 |
| Return visit (30+ min) | 61 | $5,274 | $69 |
| Short return visit (20+ min) | 14 | $599 | $40 |
Who their Medicare patients are
145 Original Medicare patients in 2024. Average age 71 · Under 65 17% · 85 and older 9% · Women 58% · Also on Medicaid 26% · Health risk score 1.61. Above the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 59% · Depression 33% · Diabetes 23% · Chronic kidney disease 23% · Coronary heart disease 22% · Cancer 14% · Atrial fibrillation 14% · COPD 12% · Heart failure 8%.
The office billed $245,382, Medicare allowed $38,904 and paid $30,169; for 855 services of 16 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 145 | 855 | 71 | 1.61 | $245,382 | $30,169 |
| 2023 | 122 | 1,377 | 71 | 1.63 | $197,202 | $27,598 |
| 2022 | 41 | 42 | 68 | 1.27 | $25,488 | $3,250 |
| 2021 | 143 | 196 | 69 | 1.46 | $98,141 | $12,773 |
| 2020 | 88 | 106 | 67 | 1.48 | $59,318 | $6,929 |
| 2019 | 122 | 160 | 69 | 1.65 | $113,112 | $11,500 |
| 2018 | 113 | 141 | 69 | 1.50 | $100,255 | $11,059 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Return visit (30+ min) | 84 | $6,877 | $65 |
| Long return visit (40+ min) | 37 | $4,863 | $108 |
2022: 1 service
| Return visit (30+ min) | 25 | $1,717 | $69 |
2021: 4 services
| Return visit (30+ min) | 92 | $7,457 | $68 |
| Long return visit (40+ min) | 16 | $1,915 | $113 |
| Short return visit (20+ min) | 32 | $1,643 | $50 |
| Telephone medical discussion with physician, 11-20 minutes | 22 | $995 | $41 |
2020: 2 services
| Long return visit (40+ min) | 33 | $3,021 | $84 |
| Return visit (30+ min) | 34 | $2,404 | $60 |
2019: 2 services
| Long return visit (40+ min) | 86 | $8,502 | $80 |
| Return visit (30+ min) | 40 | $2,399 | $56 |
2018: 2 services
| Long return visit (40+ min) | 84 | $8,391 | $83 |
| Return visit (30+ min) | 25 | $1,766 | $59 |
Drugs they prescribed that Part D paid
$7,384,635
Pharmacies billed $7,384,635 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,876) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
1,983 generic and 872 brand-name prescriptions · $7,384,635 in drug cost · 126 antibiotic prescriptions to 60 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Stelara | 154 | $4,798,837 | $31,161 |
| Skyrizi on-Body | 27 | $553,274 | $20,492 |
| Humira(Cf) | 34 | $422,419 | $12,424 |
| Rinvoq | 23 | $258,079 | $11,221 |
| Xeljanz | 16 | $170,902 | $10,681 |
See all 45 drugs
| Stelara | 154 | $4,798,837 | $31,161 |
| Skyrizi on-Body | 27 | $553,274 | $20,492 |
| Humira(Cf) | 34 | $422,419 | $12,424 |
| Rinvoq | 23 | $258,079 | $11,221 |
| Xeljanz | 16 | $170,902 | $10,681 |
| Xifaxan | 62 | $139,752 | $2,254 |
| Creon | 20 | $101,306 | $5,065 |
| Linzess | 103 | $77,157 | $749 |
| Cimzia (2 Pack) | 12 | $67,158 | $5,596 |
| Motegrity | 66 | $64,152 | $972 |
| Viberzi | 15 | $56,012 | $3,734 |
| Mesalamine | 51 | $53,358 | $1,046 |
| Zenpep | 12 | $29,709 | $2,476 |
| Pentasa | 15 | $28,776 | $1,918 |
| Dexlansoprazole Dr | 39 | $17,362 | $445 |
| Dexilant | 18 | $10,975 | $610 |
| Octreotide Acetate | 11 | $7,334 | $667 |
| Lubiprostone | 17 | $6,066 | $357 |
| Gavilyte-G | 359 | $5,827 | $16 |
| Budesonide Ec | 14 | $4,791 | $342 |
| Sod Sulf-Potass Sulf-Mag Sulf | 50 | $3,257 | $65 |
| Famotidine | 146 | $2,774 | $19 |
| Colesevelam | 16 | $2,770 | $173 |
| Omeprazole | 190 | $2,656 | $14 |
| Dicyclomine | 70 | $2,184 | $31 |
| Pantoprazole | 126 | $2,106 | $17 |
| Sutab | 11 | $1,787 | $162 |
| Budesonide Dr | 13 | $1,649 | $127 |
| Sucralfate | 47 | $1,635 | $35 |
| Peg-3350 and Electrolytes | 86 | $1,535 | $18 |
| Ondansetron | 469 | $1,436 | $3 |
| Rabeprazole | 20 | $1,231 | $62 |
| Diphenoxylate-Atropine | 30 | $1,136 | $38 |
| Esomeprazole Magnesium | 17 | $918 | $54 |
| Methotrexate | 39 | $805 | $21 |
| Gavilyte-C | 48 | $719 | $15 |
| Loperamide | 14 | $636 | $45 |
| Fluconazole | 11 | $322 | $29 |
| Insulin | 11 | $296 | $27 |
| Prednisone | 26 | $279 | $11 |
| Ondansetron Odt | 11 | $265 | $24 |
| Sodium Chloride | 34 | $224 | $7 |
| Mirtazapine | 21 | $199 | $9 |
| Amitriptyline | 23 | $187 | $8 |
| Metronidazole | 16 | $136 | $8 |
Year by year
| 2024 | 2,876 | 905 | 0% (0) | 30% | $7,384,635 |
| 2023 | 2,239 | 712 | 0% (0) | 29% | $6,070,839 |
| 2022 | 1,079 | 407 | 0% (0) | None | $1,907,370 |
| 2021 | 2,558 | 882 | 1% (13) | 43% | $5,305,937 |
| 2020 | 1,199 | 457 | 1% (11) | None | $1,924,747 |
| 2019 | 2,165 | 739 | 1% (23) | None | $2,447,329 |
| 2018 | 1,399 | 617 | 1% (18) | None | $912,133 |
| 2017 | 245 | 200 | 0% (0) | 54% | $8,924 |
| 2016 | 358 | 288 | 0% (0) | 48% | $5,728 |
| 2015 | 13 | 12 | 0% (0) | None | $256 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 33 drugs
| Stelara | 157 | $4,688,877 | $29,865 |
| Humira(Cf) | 28 | $227,056 | $8,109 |
| Xeljanz | 17 | $184,864 | $10,874 |
| Creon | 42 | $150,995 | $3,595 |
| Xifaxan | 60 | $144,414 | $2,407 |
| Mesalamine | 69 | $67,098 | $972 |
| Motegrity | 47 | $55,636 | $1,184 |
| Linzess | 54 | $43,791 | $811 |
| Dexilant | 26 | $18,913 | $727 |
| Dexlansoprazole Dr | 29 | $14,835 | $512 |
| Lubiprostone | 22 | $9,752 | $443 |
| Budesonide Ec | 21 | $7,448 | $355 |
| Gavilyte-G | 355 | $6,519 | $18 |
| Omeprazole | 160 | $3,820 | $24 |
| Hydrocortisone | 12 | $2,517 | $210 |
| Dicyclomine | 65 | $2,223 | $34 |
| Famotidine | 98 | $2,191 | $22 |
| Sod Sulf-Potass Sulf-Mag Sulf | 27 | $2,132 | $79 |
| Sutab | 12 | $2,042 | $170 |
| Pantoprazole | 60 | $1,296 | $22 |
| Budesonide Dr | 15 | $1,287 | $86 |
| Diphenoxylate-Atropine | 22 | $1,269 | $58 |
| Esomeprazole Magnesium | 17 | $1,119 | $66 |
| Sucralfate | 25 | $1,090 | $44 |
| Methotrexate | 27 | $1,012 | $37 |
| Ondansetron | 374 | $668 | $2 |
| Loperamide | 16 | $529 | $33 |
| Peg-3350 and Electrolytes | 25 | $487 | $19 |
| Ondansetron Odt | 13 | $366 | $28 |
| Gavilyte-C | 14 | $302 | $22 |
| Amitriptyline | 15 | $212 | $14 |
| Prednisone | 23 | $212 | $9 |
| Metronidazole | 13 | $150 | $12 |
2022: 23 drugs
| Stelara | 35 | $1,036,968 | $29,628 |
| Humira(Cf) | 19 | $165,136 | $8,691 |
| Creon | 24 | $145,871 | $6,078 |
| Xeljanz | 17 | $139,947 | $8,232 |
| Xifaxan | 23 | $46,334 | $2,015 |
| Mesalamine | 44 | $43,603 | $991 |
| Linzess | 51 | $32,478 | $637 |
| Dexilant | 25 | $24,949 | $998 |
| Motegrity | 21 | $14,640 | $697 |
| Pentasa | 12 | $9,260 | $772 |
| Lubiprostone | 11 | $4,947 | $450 |
| Budesonide Dr | 16 | $2,571 | $161 |
| Omeprazole | 102 | $2,264 | $22 |
| Suprep | 17 | $1,998 | $118 |
| Famotidine | 74 | $1,504 | $20 |
| Gavilyte-G | 87 | $1,445 | $17 |
| Pantoprazole | 58 | $1,404 | $24 |
| Dicyclomine | 37 | $790 | $21 |
| Peg-3350 and Electrolytes | 39 | $635 | $16 |
| Ondansetron | 114 | $577 | $5 |
| Desipramine | 13 | $537 | $41 |
| Methotrexate | 12 | $498 | $42 |
| Mirtazapine | 12 | $236 | $20 |
2021: 41 drugs
| Stelara | 147 | $3,690,809 | $25,108 |
| Humira(Cf) | 33 | $234,477 | $7,105 |
| Xifaxan | 82 | $159,885 | $1,950 |
| Creon | 44 | $145,957 | $3,317 |
| Xeljanz | 21 | $145,088 | $6,909 |
| Humira | 15 | $133,291 | $8,886 |
| Cimzia | 13 | $123,611 | $9,509 |
| Simponi | 14 | $120,248 | $8,589 |
| Mesalamine | 100 | $98,646 | $986 |
| Linzess | 98 | $51,684 | $527 |
| Motegrity | 38 | $28,455 | $749 |
| Budesonide Er | 16 | $20,334 | $1,271 |
| Dexilant | 28 | $19,545 | $698 |
| Amitiza | 27 | $18,388 | $681 |
| Suprep | 116 | $13,009 | $112 |
| Budesonide Ec | 21 | $8,380 | $399 |
| Protonix | 11 | $5,860 | $533 |
| Omeprazole | 185 | $4,307 | $23 |
| Budesonide Dr | 20 | $3,241 | $162 |
| Peg-3350 and Electrolytes | 247 | $3,168 | $13 |
| Plenvu | 20 | $2,613 | $131 |
| Diphenoxylate-Atropine | 29 | $2,599 | $90 |
| Pantoprazole | 105 | $2,525 | $24 |
| Famotidine | 104 | $2,338 | $22 |
| Colestipol | 12 | $2,202 | $184 |
| Dicyclomine | 78 | $2,015 | $26 |
| Sucralfate | 25 | $1,992 | $80 |
| Ondansetron | 288 | $1,848 | $6 |
| Clenpiq | 11 | $1,786 | $162 |
| Gavilyte-G | 126 | $1,689 | $13 |
| Esomeprazole Magnesium | 16 | $1,643 | $103 |
| Desipramine | 31 | $1,452 | $47 |
| Lansoprazole | 19 | $1,051 | $55 |
| Methotrexate | 17 | $722 | $42 |
| Loperamide | 12 | $491 | $41 |
| Peg 3350-Electrolyte | 28 | $430 | $15 |
| Mirtazapine | 28 | $426 | $15 |
| Prednisone | 30 | $263 | $9 |
| Golytely | 18 | $242 | $13 |
| Metronidazole | 15 | $167 | $11 |
| Vitamin D2 | 12 | $30 | $3 |
2020: 27 drugs
| Stelara | 47 | $1,030,640 | $21,929 |
| Creon | 48 | $125,059 | $2,605 |
| Cimzia | 14 | $109,835 | $7,845 |
| Entyvio | 12 | $84,072 | $7,006 |
| Mesalamine | 61 | $58,055 | $952 |
| Xifaxan | 28 | $51,243 | $1,830 |
| Linzess | 37 | $21,853 | $591 |
| Amitiza | 21 | $14,892 | $709 |
| Budesonide Ec | 23 | $14,326 | $623 |
| Motegrity | 18 | $14,188 | $788 |
| Dexilant | 18 | $10,592 | $588 |
| Movantik | 11 | $5,301 | $482 |
| Sucralfate | 20 | $2,655 | $133 |
| Suprep | 20 | $2,114 | $106 |
| Omeprazole | 96 | $1,561 | $16 |
| Gavilyte-G | 106 | $1,432 | $14 |
| Diphenoxylate-Atropine | 17 | $1,308 | $77 |
| Lansoprazole | 15 | $1,233 | $82 |
| Pantoprazole | 39 | $1,176 | $30 |
| Desipramine | 17 | $1,063 | $63 |
| Esomeprazole Magnesium | 15 | $1,025 | $68 |
| Dicyclomine | 33 | $936 | $28 |
| Peg-3350 and Electrolytes | 66 | $823 | $12 |
| Famotidine | 26 | $614 | $24 |
| Ondansetron | 142 | $457 | $3 |
| Methotrexate | 14 | $338 | $24 |
| Prednisone | 15 | $169 | $11 |
2019: 38 drugs
| Stelara | 64 | $1,355,513 | $21,180 |
| Simponi | 22 | $242,701 | $11,032 |
| Creon | 62 | $119,355 | $1,925 |
| Cimzia | 15 | $112,464 | $7,498 |
| Mesalamine | 123 | $96,064 | $781 |
| Xifaxan | 52 | $79,231 | $1,524 |
| Viberzi | 16 | $34,450 | $2,153 |
| Linzess | 67 | $34,449 | $514 |
| Budesonide Ec | 29 | $20,029 | $691 |
| Apriso | 11 | $19,187 | $1,744 |
| Motegrity | 26 | $16,425 | $632 |
| Dexilant | 37 | $14,220 | $384 |
| Amitiza | 25 | $10,220 | $409 |
| Movantik | 13 | $5,364 | $413 |
| Suprep | 52 | $5,239 | $101 |
| Gavilyte-G | 346 | $4,832 | $14 |
| Balsalazide Disodium | 22 | $4,601 | $209 |
| Esomeprazole Magnesium | 29 | $2,610 | $90 |
| Omeprazole | 145 | $2,584 | $18 |
| Mercaptopurine | 20 | $2,501 | $125 |
| Desipramine | 25 | $2,396 | $96 |
| Lansoprazole | 13 | $2,352 | $181 |
| Diphenoxylate-Atropine | 21 | $1,829 | $87 |
| Pantoprazole | 83 | $1,681 | $20 |
| Rabeprazole | 12 | $1,577 | $131 |
| Moviprep | 13 | $1,371 | $105 |
| Ranitidine | 74 | $1,252 | $17 |
| Dicyclomine | 71 | $1,250 | $18 |
| Ondansetron | 266 | $755 | $3 |
| Sucralfate | 20 | $690 | $35 |
| Peg-3350 and Electrolytes | 42 | $534 | $13 |
| Ondansetron Odt | 13 | $419 | $32 |
| Methotrexate | 12 | $339 | $28 |
| Famotidine | 21 | $279 | $13 |
| Peg 3350-Electrolyte | 26 | $264 | $10 |
| Prednisone | 12 | $250 | $21 |
| Ciprofloxacin | 14 | $189 | $14 |
| Metronidazole | 16 | $160 | $10 |
2018: 25 drugs
| Stelara | 27 | $498,157 | $18,450 |
| Simponi | 13 | $136,573 | $10,506 |
| Creon | 40 | $63,713 | $1,593 |
| Xifaxan | 27 | $38,536 | $1,427 |
| Mesalamine | 31 | $23,399 | $755 |
| Linzess | 29 | $13,009 | $449 |
| Apriso | 12 | $11,279 | $940 |
| Budesonide Ec | 15 | $9,580 | $639 |
| Dexilant | 24 | $8,403 | $350 |
| Amitiza | 20 | $7,520 | $376 |
| Suprep | 41 | $3,873 | $94 |
| Gavilyte-G | 278 | $3,507 | $13 |
| Moviprep | 25 | $2,515 | $101 |
| Desipramine | 12 | $1,474 | $123 |
| Omeprazole | 64 | $855 | $13 |
| Ranitidine | 43 | $740 | $17 |
| Peg-3350 and Electrolytes | 68 | $740 | $11 |
| Pantoprazole | 51 | $653 | $13 |
| Ondansetron | 242 | $575 | $2 |
| Sucralfate | 13 | $426 | $33 |
| Dicyclomine | 36 | $395 | $11 |
| Peg 3350-Electrolyte | 27 | $294 | $11 |
| Azathioprine | 11 | $224 | $20 |
| Metronidazole | 14 | $207 | $15 |
| Ciprofloxacin | 12 | $110 | $9 |
2017: 7 drugs
| Peg 3350-Electrolyte | 75 | $1,203 | $16 |
| Gavilyte-G | 34 | $448 | $13 |
| Gavilyte-N | 24 | $411 | $17 |
| Peg-3350 and Electrolytes | 31 | $361 | $12 |
| Omeprazole | 24 | $208 | $9 |
| Peg 3350-Electrolyte | 13 | $141 | $11 |
| Gavilyte-C | 11 | $128 | $12 |
2016: 9 drugs
| Peg 3350-Electrolyte | 119 | $2,146 | $18 |
| Gavilyte-N | 72 | $1,256 | $17 |
| Trilyte With Flavor Packets | 21 | $387 | $18 |
| Peg-3350 and Electrolytes | 30 | $348 | $12 |
| Gavilyte-G | 23 | $337 | $15 |
| Omeprazole | 38 | $281 | $7 |
| Peg 3350-Electrolyte | 15 | $172 | $11 |
| Pantoprazole | 11 | $82 | $7 |
| Ciprofloxacin | 11 | $54 | $5 |
Money from drug and device companies
$90 in 2025
| 2025 | 2 | 4 | None | $90 |
| 2024 | 3 | 5 | None | $150 |
| 2023 | 3 | 14 | None | $305 |
| 2022 | 3 | 13 | None | $251 |
| 2021 | 3 | 13 | None | $235 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Skyrizi | $53 | 2 payments
|
| Janssen Biotech | Tremfya | $38 | 2 payments
|
See all 4 published payments
| Abbvie | Meals · 2025-12-24 | Skyrizi | $21 |
| Janssen Biotech | Meals · 2025-12-04 | Tremfya | $20 |
| Abbvie | Meals · 2025-11-05 | Skyrizi | $31 |
| Janssen Biotech | Meals · 2025-10-13 | Tremfya | $18 |
See earlier years (2024, 2023, 2022, 2021)
2024: $150
| Janssen Biotech | Stelara | $78 | 3 payments
|
| Abbvie | Rinvoq | $44 | 1 payment
|
| Ironwood Pharmaceuticals | Linzess | $27 | 1 payment
|
2023: $305
| Ironwood Pharmaceuticals | Linzess | $164 | 8 payments
|
| Janssen Biotech | Stelara | $120 | 5 payments
|
| Takeda Pharmaceuticals U.S.A. | Gattex | $21 | 1 payment
|
2022: $251
| Janssen Biotech | Stelara | $204 | 10 payments
|
| Abbvie | Linzess | $27 | 2 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $20 | 1 payment
|
2021: $235
| Ironwood Pharmaceuticals | Linzess | $141 | 8 payments
|
| AbbVie | Linzess | $50 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Gattex | $45 | 2 payments
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1720467509
- Licence
- CA 95001351, CA 95030449
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 363LA2100X (363LA2100X); Federal specialty code 163W00000X (163W00000X)
- Mailing address
- 1046 Mason St Apt 5, San Francisco, CA, 94108
- NPI first listed
- 2015-05-26
- NPI last updated
- 2015-05-26
This is when the NPI record was last certified, not a medical board exam.